Clinical Trials Browser

Interventional × niraparib × 30 days × Clear all

NCT03748641 2026-06-05

MAGNITUDE

Phase 3 Active not recruiting

765 enrolled 16 charts 1 FDA

Prostatic Neoplasms, Castration-Resistant

NCT04497844 2026-06-05

AMPLITUDE

Phase 3 Active not recruiting

696 enrolled 15 charts 1 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT04577833 2026-06-05

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT05784012 2026-06-04

RADIAN

Phase 1/2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05523440 2026-06-03

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

Phase 2 Terminated

9 enrolled 10 charts

Ovarian Neoplasms, Endometrial Neoplasms

NCT06412120 2026-06-03

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

Phase 4 Recruiting

Ovarian Neoplasms

NCT06433219 2026-06-03

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Phase 2 Active not recruiting

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

NCT06915025 2026-06-02

OVATION-3

Phase 3 Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03651206 2026-06-01

ROCSAN

Phase 2/3 Recruiting

GynecologicSarcoma

Ovarian Carcinosarcoma

NCT04992013 2026-06-01

Niraparib in Tumors Metastatic to the CNS

Phase 2 Active not recruiting

Neoplasm Metastasis, Central Nervous System Neoplasms

NCT05718323 2026-05-29

RAISE

Phase 2 Recruiting

SCLC,Extensive Stage

NCT04037254 2026-05-20

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

Phase 1/2 Completed

22 enrolled 13 charts

Prostatic Neoplasms

NCT05615818 2026-05-19

SAFIR-ABC10

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT04947254 2026-05-15

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT04030559 2026-05-14

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

Phase 2 Terminated

11 enrolled 7 charts

Prostatic Neoplasms